Condition
ALK+ Non-Small-Cell Lung Carcinoma clinical trials and research
As of November 12, 2026, Find a Trial lists 2 ALK+ Non-Small-Cell Lung Carcinoma clinical trials that are recruiting, at sites in 2 countries (most in United States (1), France (1)). By phase: Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 2Countries
All recruiting trials (2)
-
NXP900 with Lorlatinib in ALK-positive NSCLC
This study tests whether adding NXP900 to lorlatinib helps people with ALK-positive non-small cell lung cancer who have already received prior therapy.
-
Effectiveness and safety of Lorlatinib for untreated ALK-positive lung cancer patients in France
This study is testing if Lorlatinib is safe and effective for adults in France who have not yet received treatment for ALK-positive lung cancer.
Related topics
Quick answers
How many ALK+ Non-Small-Cell Lung Carcinoma clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (1 trial), France (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.